07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...
07:00 , Aug 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Genentech (NYSE:DNA) disclosed in an SEC filing last week details of the retention and severance plans it has put in place to cover “substantially all” of its employees and executives as the biotech negotiates over...